The Ohio State University Wexner Medical Center

We don’t know if we don’t ask”: Reply to Tham, et al

Jennica N Johns, MD, Kathleen O Lindell, PhD, RN, ATSF, FAAN; We don’t know if we don’t ask”: Reply to Tham, et al, Annals of the American Thoracic Society

Reasonable Exceptions From Unreasonable Policies: Requiring Treatment Agreements for Long‐Term Opioid Therapy and Exemptions for Cancer and Terminal Illness

Since drug overdose deaths began increasing in the United States, policy makers and the medical community have developed tools to try to address the crisis. Opioid Treatment Agreements (OTAs) are one such tool which purportedly seek to promote shared decision-making and informed...

Duration of Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest

Importance Therapeutic hypothermia is widely used for neuroprotection following cardiac arrest, but clinical trials have not consistently demonstrated improved neurological outcomes, and the optimal duration of cooling remains uncertain. Objective To determine the duration of the...

Acute Interstitial Nephritis after Single Dose of Ketorolac.

Acute interstitial nephritis (AIN) is an immunologically mediated cause of acute kidney injury (AKI), most often drug-induced, with NSAIDs being a leading culprit. We present a 39-year-old woman who developed biopsy- proven AIN following a single intramuscular dose of ketorolac,...

Obinutuzumab Induces Histological Remission and Deep Kidney Parenchymal B-Cell Depletion in Patients with Lupus Nephritis: Exploratory Analyses of the Phase III REGENCY Trial

Objectives The REGENCY trial ( NCT04221477 ) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). These exploratory analyses aimed to...